Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III multicenter study of relugolix tablets in hormone-sensitive advanced prostate cancer
CTR20262234Phase 3Active
- Sponsor
- Fangsheng Jianmeng Pharmaceutical
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tissue-plasminogen activator in prostate cancer (PCa) (2 arms), sponsored by Fangsheng Jianmeng Pharmaceutical. Primary endpoint: Sustained castration rate of serum testosterone. Started Jun 2026; status: active.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20262234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262234.